Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement

Nov

11

Today In Oncology

CTCL Denileukin Diftitox May Improve HRQoL

Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer Risk

Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer

KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC

FDA Approves Pimicotinib for Symptomatic TGCT

Advertisement

© 2026 HSP News Service, L.L.C.